1 PRODUCT NAME
MESTINON 60 mg Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 60 mg pyridostigmine bromide.

Excipients with known effect:
Lactose
For a full list of excipients see section 6.1.

3 PHARMACEUTICAL FORM
Tablet

MESTINON tablets are practically white, round, flat-faced tablets with beveled edges. Engraved “Mestinon 60” on outer perimeter and quadrisection scored on the other side.

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Myasthenia gravis, paralytic ileus, and postoperative urinary retention.

4.2 Dose and method of administration
MESTINON tablets are for oral administration. MESTINON has a gradual onset of effect (generally 30-60 minutes).

Myasthenia Gravis
Adults
Doses of 30 to 120 mg by mouth are given at intervals throughout the day when maximum strength is needed (for example on rising and before meal times). The usual duration of action of a dose is three to four hours in the daytime but a longer effect (six hours) is often obtained with a dose taken on retiring for bed.

The total daily dose is usually in the range of 5-20 tablets but some patients may require doses higher than these.

Paediatric Population
Children under 6 years old should receive an initial dose of half a tablet (30 mg) of MESTINON. Children 6-12 years old should receive one tablet (60 mg). Dosage should be increased gradually, in increments of 15-30 mg daily, until maximum improvement is obtained. Total daily requirements are usually in the range of 30-360 mg by mouth.

Newborn Infants
Neostigmine has generally been preferred in the treatment of neonatal myasthenia. However MESTINON can be given, particularly if neostigmine proves unsuitable on account of pronounced cholinergic effects.
The dosage requirements of MESTINON range from 5-10 mg orally every four hours, given 30-60 minutes before feeding. Treatment is not usually required beyond eight weeks of age except in the rare conditions of congenital and familial infantile myasthenia.

Other indications (paralytic ileus, post-operative urinary retention)

**Adults**
The usual dose is 1 to 4 tablets by mouth.

**Children**
The dosage is 15 to 60 mg per day by mouth.
The frequency of these doses may be varied according to the needs of the patient.

**Special Populations**

**Elderly**
There are no specific dosage recommendations for MESTINON in elderly patients.

**Renal impairment**
MESTINON is mainly excreted unchanged by the kidney, therefore lower doses may be required in patients with renal disease and treatment should be based on titration of drug dosage to effect.

**Hepatic impairment**
There are no specific dosage recommendations for Mestinon in patients with hepatic impairment.

4.3 **Contraindications**
MESTINON is contraindicated in patients with:

- Known hypersensitivity to the active substance, bromides or to any of its excipients listed in section 6.1.
- Mechanical gastrointestinal or urinary obstruction.

MESTINON should not be used in conjunction with depolarising muscle relaxants such as suxamethonium as neuromuscular blockade may be potentiated and prolonged apnoea may result.

4.4 **Special warnings and precautions for use**

Hypersensitivity reactions may occur in susceptible individuals.

Extreme caution is required when administering MESTINON to patients with bronchial asthma.

Care should be taken in patients with:

- Bradycardia
- Recent coronary occlusion
- Hypotension
- Vagotonia
- Epilepsy or Parkinsonism.

There is no evidence to suggest that MESTINON has any special effects in the elderly. However, elderly patients may be more susceptible to dysrhythmias than the younger adult.

MESTINON is mainly excreted unchanged by the kidney, therefore lower doses may be required in patients with renal disease and treatment should be based on titration of drug dosage to effect.
MESTINON should not be given during cyclopropane or halothane anaesthesia; however, it may be used after withdrawal of these agents.

The requirement of MESTINON is usually markedly decreased after thymectomy or when additional therapy (steroids, immunosuppressant medicines) is given.

When relatively large doses of MESTINON are taken by myasthenic patients it may be necessary to give atropine or other anticholinergic medicines to counteract the muscarinic effects. It should be noted that the slower gastrointestinal motility caused by these medicines may affect the absorption of oral MESTINON.

In all patients the possibility of 'cholinergic crisis' due to overdosage of MESTINON, and differentiation from 'myasthenic crisis' due to increased severity of the disease, must be borne in mind. Both types of crisis are manifested by increased muscle weakness, but whereas myasthenic crisis may require more intensive anticholinesterase treatment, cholinergic crisis calls for immediate discontinuation of this treatment and institution of appropriate supportive measure, including respiratory assistance.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicines and other forms of interaction

Immunosuppressant drugs
The requirement for pyridostigmine bromide could be decreased when additional therapy (steroids, immunosuppressant drugs) is given although peak plasma concentration and AUC of pyridostigmine may decrease by high doses of corticosteroids.

Antimuscarinics
Atropine and hyoscine antagonise the muscarinic effects of pyridostigmine bromide.

Muscle relaxants
Pyridostigmine antagonises the effect of non-depolarising muscle relaxants (e.g. pancuronium and vecuronium). Pyridostigmine may prolong the effect of depolarising muscle relaxants (e.g. suxamethonium).

4.6 Fertility, pregnancy and lactation

Pregnancy
Category C

The safety of MESTINON during pregnancy or lactation has not been established.

The maternal requirement for this medicine in the context of myasthenia gravis may be absolute. Cholinergic effects in the neonate are rare.

Although the possible hazards to mother and child must be weighed against the potential benefits in every case, experience with MESTINON in pregnant patients with myasthenia gravis has revealed no untoward effect of the medicine on the course of pregnancy.
As the severity of myasthenia gravis often fluctuates considerably, particular care is required to avoid cholinergic crises due to overdosage of the medicine, but otherwise management is no different from that in non-pregnant patients.

**Lactation**
Observations indicated that only negligible amounts of MESTINON are secreted in breast milk; nevertheless, due regard should be paid to possible effects on the breast-feeding infant.

**4.7 Effects on ability to drive and use machines**
Due to miosis and accommodation disorders caused by pyridostigmine bromide or an inadequate treatment of myasthenia gravis, MESTINON may impair visual acuity and consequently the ability to react as well as the ability to drive and use machines.

**4.8 Undesirable effects**
As with all cholinergic products, MESTINON may have unwanted functional effects on the autonomic system. Muscarine-like adverse effects may be exhibited as nausea, vomiting, diarrhoea, abdominal cramps, increased peristaltic and increased bronchial secretion, salivation, bradycardia and miosis.

The primary nicotinic effects are muscle spasms, fasciculation and muscular weakness.

Adverse reactions are listed below according to system organ class and frequency. Frequencies are defined according to the following convention:
Very Common (≥1/10), Common (≥1/100 to <1/100), Uncommon (≥1/1000 to < 1/100), Rare (≥1/10,000 to <1/1000), Very rare (<1/10,000), Not known (cannot be estimated from the available data).

**Eye disorders**
Frequency not known: Miosis, increased lacrimation, accommodation disorders.

**Cardiac disorders**
Frequency not known: Arrhythmia (including bradycardia, tachycardia, AV block), as well as syncope and hypotension (see section 4.9).

**Respiratory, thoracic and mediastinal disorders**
Frequency not known: Increased bronchial secretion combined with bronchoconstriction.

**Gastrointestinal disorders**
Frequency not known: Nausea, vomiting, diarrhoea, abdominal cramps, gastrointestinal hypermotility, salivary hypersecretion.

**Skin and subcutaneous tissue disorders**
Frequency not known: Rash (disappears usually soon after ceasing of the medicine. Bromide containing medicines should no longer be used.), hyperhydrosis.

**Musculoskeletal and connective tissue disorders**
Frequency not known: Increased muscle weakness, fasciculation, tremors and muscle cramps or muscle hypotonia (see section 4.9).
Renal and urinary disorders
Frequency not known: Urinary urgency

Because these symptoms may be an indication of cholinergic crisis, the physician should be notified immediately to clarify the diagnosis (see section 4.9).

**Reporting of suspected reactions**
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)

**4.9 Overdose**
Signs of overdosage due to muscarinic effects may include abdominal cramps, increased peristalsis, diarrhoea, nausea and vomiting, increased bronchial secretions, salivation, diaphoresis and miosis.

Nicotinic effects consist of muscular cramps, fasciculation and general weakness. Bradycardia and hypotension may also occur.

Artificial ventilation should be instituted if respiration is severely depressed.

Atropine sulphate 1 to 2 mg intravenously is an antidote to the muscarinic effects.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

**5 PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**
Pharmacotherapeutic group: Nervous system, parasympathomimetics, anticholinesterases, pyridostigmine. ATC Code: N07AA02.

Mestinon is an antagonist to cholinesterase, the enzyme that normally destroys acetylcholine. MESTINON can briefly be described, therefore, as the potentiation of naturally occurring acetylcholine. MESTINON has a more prolonged action than neostigmine although it is somewhat slower to take effect (generally taking 30-60 minutes). Because it has a weaker 'muscarinic' action than neostigmine, it is usually much better tolerated by myasthenic patients in whom the longer action is also an advantage.

**5.2 Pharmacokinetic properties**
Oral pyridostigmine is poorly absorbed. Maximum plasma concentrations occur at 1 to 2 hours and it is eliminated by the kidney largely unchanged with a half-life of 3 to 4 hours.

**5.3 Preclinical safety data**
There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the datasheet.
6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Colloidal silicon dioxide
Lactose
Stearic acid

6.2 Incompatibilities
Not applicable

6.3 Shelf life
36 months

6.4 Special precautions for storage
Store at or below 25°C.
Protect from light.
Protect from moisture.

6.5 Nature and contents of container
HDPE bottle, polypropylene child resistant cap, pulp liner with Al/PET heat seal.
Pack size: 100 tablets

6.6 Special precautions for disposal
No special requirements.

7 MEDICINE SCHEDULE
Prescription

8 SPONSOR
iNova Pharmaceuticals (New Zealand) Limited
c/- Simpson Grierson
88 Shortland Street,
Auckland 1141

Toll-free number: 0508 375 394

9 DATE OF FIRST APPROVAL
22 October 2009

10 DATE OF REVISION OF THE TEXT
10 May 2022
## SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Date</th>
<th>Changes</th>
</tr>
</thead>
</table>
| 10 May 2022   | Section 3 – Pharmaceutical Form.  
                Tablet description updated to remove logo inscription “V”                                                                 |
| 25 May 2018   | Datasheet reformatted.  
                Section 4.2: Added statement for hepatic impairment consistent with EU SPC.  
                Section 4.2: Renal impairment statement moved from Warnings and Precautions to section 4.2.  
                Section 4.4.: The following statement: “The requirement of MESTINON is usually markedly decreased after thymectomy or when additional therapy (steroids, immunosuppressant medicines) is given. When relatively large doses of MESTINON are taken by myasthenic patients it may be necessary to give atropine or other anticholinergic medicines to counteract the muscarinic effects. It should be noted that the slower gastrointestinal motility caused by these medicines may affect the absorption of oral MESTINON. In all patients the possibility of ‘cholinergic crisis’ due to overdosage of MESTINON, and differentiation from ‘myasthenic crisis’ due to increased severity of the disease, must be borne in mind. Both types of crisis are manifested by creased muscle weakness, but whereas myasthenic crisis may require more intensive anticholinesterase treatment, cholinergic crisis calls for immediate discontinuation of this treatment and institution of appropriate supportive measure, including respiratory assistance” moved from Dosage and Administration to section 4.4 consistent with the EU SPC.  
                Section 4.4: added:  
                Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.  
                Section 4.5: The requirement for pyridostigmine bromide could be decreased when additional therapy (steroids, immunosuppressant drugs) is given peak plasma concentration and AUC of pyridostigmine may decrease by high doses of corticosteroids. – moved from Dosage & Administration to section 4.5  
                Section 4.6: moved Pregnancy and lactation from Contraindications to section 4.6 consistent with EU SPC  
                Section 4.6 added: The maternal requirement for this medicine in the context of myasthenia gravis may be absolute. Cholinergic effects in the neonate are rare. – statement from Prescribing medicines in pregnancy |
<table>
<thead>
<tr>
<th>Section 4.8 updated to be consistent with the EU SPC and with statements appearing in section 4.9.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 5.3 added: There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the datasheet.</td>
</tr>
<tr>
<td>Section 6 updated to be consistent with the MESTINON TPDR. Added: HDPE bottle, polypropylene child resistant cap, pulp liner with Al/PET heat seal.</td>
</tr>
<tr>
<td>Section 8: Sponsor name and address changed.</td>
</tr>
</tbody>
</table>